It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2017

Dementia Discovery Fund Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes
Nerina Coppini, 28 February 2017

The Dementia Discovery Fund announces the acquisition of a >500,000 compound, CNS-biased small molecule library The DDF and Aptuit enter into a strategic partnership to leverage the DDF library and Aptuit’s capabilities for dementia drug discovery London, Boston, Greenwich - February 28, 2017 – The Dementia Discovery Fund (‘DDF’), a venture...

SAMDI Tech, Inc. and Aptuit Announce Drug Discovery Screening Partnership
Nerina Coppini, 7 February 2017

CHICAGO, IL – February 7, 2017 – SAMDI Tech, Inc. and Aptuit, LLC are partnering to broaden their portfolio of assay development and high-throughput drug discovery services in Europe and North America. The partnership provides early-stage drug discovery researchers with access to SAMDI Tech’s unique label-free platform as well as Aptuit’s broad...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard